Prevention Breakthrough: A Historic HIV Innovation Delivered at Unprecedented Speed
7 Articles
7 Articles
The Pan American Health Organization (OPAS) announced that a new agreement with the pharmaceutical company Gilead Sciences will facilitate access by 14 countries to lenacapavir, a long-term drug that protects against HIV infection. In the same statement, the entity stated that "Gilead has also undertaken to advance in a technology transfer process in Brazil, with the aim of facilitating the local production of lenacapavir in the future." The agr…
Lenacapavir already has Anvisa's endorsement, but arriving at SUS still depends on price and evaluation for incorporation
Geneva – The Global Fund for the Control of AIDS, Tuberculosis and Malaria aims to make HIV pre-exposure prevention (PrEP) with the active substance lenacapavir more accessible than previously in the coming months. After the long-acting drug was first introduced in nine African countries by June 2026, this is to be achieved by the end of the...
Pharmaceutical firmed agreement with Opas to increase access to lenacapavir, a HIV prevention medicine applied twice a year
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
